LOGIN  |  REGISTER
Amneal Pharmaceuticals
Assertio

Clover Health to Report Second Quarter 2023 Financial Results on August 8, 2023

July 11, 2023 | Last Trade: US$3.21 0.12 -3.60

FRANKLIN, Tenn., July 11, 2023 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today announced that it will report second quarter 2023 financial results after market close on Tuesday, August 8, 2023. On that day management will host a conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s business and financial results.

Second Quarter Conference Call and Webcast Details:

  • What: Clover Health Second Quarter 2023 Earnings Conference Call
  • When: Tuesday, August 8, 2023, at 5:00 p.m. ET
  • Dial In: To access the call via telephone please dial 800-274-8461 (for U.S. callers) or 203-518-9783 (for callers outside the U.S.) and enter the conference ID: CLOVQ223
  • Webcast: A live and archived webcast of the conference call will be accessible from the Investor Relations section of the Company’s website at https://investors.cloverhealth.com/ for 12 months

About Clover Health

Clover Health (Nasdaq: CLOV) is a physician enablement company committed to bringing access to great healthcare to everyone on Medicare. This includes a health equity-based focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes. We operate two distinct lines of business: Insurance and Non-Insurance. Through our Insurance line of business, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. Our Non-Insurance line of business similarly aims to reduce cost-of-care while enhancing the quality of care for patients enrolled in Original Medicare.

Press Contact:
Andrew Still-Baxter
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations Contact:
Ryan Schmidt
This email address is being protected from spambots. You need JavaScript enabled to view it.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page